Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US6764681B2 · kind B2 · utility
6Cited by
12References
57Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Dec 5, 2000 |
| Grant date | Jul 20, 2004 |
| Priority date | — |
| Expiry date | Dec 5, 2020 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/205
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods of using inhibitors of the CD2/LFA-3 interaction in treating skin conditions characterized by increased T cell activation and abnormal antigen presentation in the dermis and epidermis in mammals, including humans. Such conditions include psoriasis, UV damage, e.g., photoaging, atopic dermatitis, cutaneous T cell lymphoma such as mycosis fungoides, allergic and irritant contact dermatitis, lichen planus, alopecia areata, pyoderma gangrenosum, vitiligo, ocular cicatricial pemphigoid, and urticaria.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.